American Journal of BioMedicine
Volume 11, Issue 2, Pages 85-95 | http://dx.doi.org/10.18081/2333-5106/2023.11/85
Mengyang Liu, Xia Wang, Jun Wu, Peng Li 1*
Received 31 January 2023 Revised 11 March 2023 Accepted 27 April 2023 Published 26 May 2023
A significant transcription factor that is involved in the regulation of numerous cellular functions is the tumor suppressor p53. In disease, p53 weakens cell expansion in light of different boosts, including DNA harm, supplement hardship, hypoxia, and hyperproliferative signs, along these lines forestalling growth arrangement. It was detailed that the proficiency of Microarray and ABI 310 framework in distinguishing proof a wide range of p53 quality transformations. Microarray and ABI 310 analysis were used in this study to find p53 gene mutations in archived breast cancer tissues. Breast tissues from cancer patients who had been diagnosed with breast cancer were collected for this purpose and paraffin-embedded after being formalin-fixed. DNA was removed by the Microdissection technique and was cleaned with Microcon 50 channels (Millipore) prior to performing PCR. Twelve of the samples that were analyzed had ABI 310 system mutations in the p53 gene, the genomic DNA was acquired from micro-dissected tests without laser. The ABI 310 system identified p53 gene mutations in three of the nine ESCC specimens from patients who were examined by microarray. In laser-miniature analyzed examples changes were distinguished by ABI 310 framework. The extricated DNA obtained from laser miniature took apart examples was deficient for the evaluation of p53 quality changes with Microarray. It was resolved that Microarray was reliant upon how much tissues were utilized in DNA extraction. The resulting data of this study showed that selecting the appropriate method for extracting DNA from test samples in order to evaluate the p53 gene mutation is crucial. The ABI 310 system and Microarray were able to detect p53 gene mutations (for exons 5-8) with an efficiency of 99.6% and 27%, respectively. Consequently, involving new tissues for Microarray analysis is suggested. In conclusion, the application of Microarray to identify mutation for p53 gene, in breast cancer tissues, will be necessary for central hospitals, where fresh tissue samples are available easily.
Keywords: p53; DNA; Framework; Breast cancer
Copyright: © 2023 Peng et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
|1. Siddig A, Tengku Din TADA, et al. The Unique Biology behind the Early Onset of Breast Cancer. Genes 2021; 12:372.
|2. Berger ER, Golshan M. Surgical Management of Hereditary Breast Cancer. Genes 2021; 12:1371.
|3. LaDuca H, Polley EC, Yussuf A, et al. A clinical guide to hereditary cancer panel testing: Evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet. Med 2020; 22:407-415.
|4. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362:849-52.
|5. Kurian AW, Bernhisel R, Larson K, et al. Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women with Postmenopausal Breast Cancer. JAMA 2020; 323:995-997.
|6. Pitolli C, Wang Y, Mancini M, Shi Y, Melino G, Amelio I. Do Mutations Turn p53 into an Oncogene? Int J Mol Sci 2019 20.
|7. Martínez-Galán J, Torres-Torres B, Núñez MI, et al. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer 2014; 14:59.
|8. Helton ES, Chen X. p53 modulation of the DNA damage response. J Cell Biochem 2007; 100:883-96.
|9. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 2011; 13:223.
|10. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011; 13:224.
|11. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-12.
|12. Gottifredi V, Prives C. Molecular biology. Getting p53 out of the nucleus. Science 2001; 292:1851-2.
|13. Huang Y, Nayak S, Jankowitz R, Davidson NE, Oesterrich S. Epigenetics in breast cancer: what's new? Breast Cancer Res 2011; 13:225.
|14. Mijit M, Caracciolo V, Melillo A, Amicarelli F, Giordano A. Role of p53 in the Regulation of Cellular Senescence. Biomolecules 2020. 10.
|15. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res 2011; 13:228.
|16. Giono LE, Manfredi JJ. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 2006; 209:13-20.
|17. Dvorak HF. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-1659.
|18. Georgakilas AG, Martin OA, Bonner WM. p21: A Two-Faced Genome Guardian. Trends Mol Med 2017; 23:310-9.
|19. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol 2014; 5:412-24.
|20. Ungerleider NA, Rao SG, Shahbandi A, et al. Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. Breast Cancer Res. 2018; 20:115.
|21. Lai H, Ma F, Trapido E, Meng L, Lai S. Spectrum of p53 tumor suppressor gene mutations and breast cancer survival. Breast Cancer Res Treat 2004; 83:57-66.
|22. Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH. et al. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat 2017; 163:263-72.
|23. Conceição ED. Multivariate analyses of triple-negative breast cancer compare with non-triple-negative breast cancer: A multicenter retrospective study. American Journal of BioMedicine 2022; 10(1):13-24.|
|24. Bargonetti J, Prives C. Gain-of-function mutant p53: history and speculation. J Mol Cell Biol 2019; 11:605-9.
|25. Murphy KL, Dennis AP, Rosen JM. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J 2000; 14:2291-302.
|26. Zhu J, Sammons MA, Donahue G, Dou Z, et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 2015; 525:206-11.
|27. Tan BS, Tiong KH, Choo HL, et al. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF) Cell Death Dis 2015; 6:e1826.
|28. A-Amran FG, Al-khirsani H. Relationship of the expression of IL-32 on NF-κB and p-p38 MAP kinase pathways in human esophageal cancer. Journal of Clinical Oncology 2012; 30:4_suppl, 59-59.
|29. Di Agostino S, Strano S, Emiliozzi V, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006; 10:191-202.
|30. Horigome E, Fujieda M, Handa T, Katayama A, Ito M, Ichihara A. et al. Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling. Oncotarget 2018; 9:34554-66.
|31. Forslund A, Zeng Z, Qin LX, Rosenberg S, Ndubuisi M, Pincas H. et al. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers. Mol Cancer Res 2008; 6:205-11.
|32. Wang W, Qin JJ, Voruganti S, et al. The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Nat Commun 2014; 5:5086.
|33. Qin JJ, Wang W, Sarkar S, Voruganti S, Agarwal R, Zhang R. Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy. Oncotarget 2016; 7:32566-78.
|34. Qin JJ, Wang W, Voruganti S, Wang H, Zhang WD, Zhang R. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. Oncotarget 2015; 6:2623-40.
|35. Li Y, Yang J, Aguilar A, et al. Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. J Med Chem 2019; 62:448-66.
|36. Gluck WL, Gounder MM, Frank R, et al. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Invest New Drugs 2020; 38:831-43.
|37. pinnler C, Hedstrom E, Li H, et al. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX. Cell Death Differ 2011; 18:1736-45.
|38. Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10:1321-8.
|39. AI-Timimi A, Yousi NG. Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: pathological correlation and prognostic indicators. American Journal of BioMedicine 2016; 4(3):265-275.|
|40. Liu SJ, Zhao Q, Peng C, et al. Design, synthesis, and biological evaluation of nitroisoxazole-containing spiro[pyrrolidin-oxindole] derivatives as novel glutathione peroxidase 4/mouse double minute 2 dual inhibitors that inhibit breast adenocarcinoma cell proliferation. Eur J Med Chem 2021; 217:113359.
Liu M, Wang X, Wu J, Li P. p53 gene mutations among patients involved with breast cancer: types of detection. American Journal of BioMedicine 2023; 11(2):85-95.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in American Journal of BioMedicine are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.